Related by context. All words. (Click for frequent words.) 70 Randomized Study 64 Thromboembolism 64 Renal Artery 63 Observational Study 62 NSABP B 62 Carotid Stenting 62 Acute Myocardial Infarction 62 Cardiovascular Outcomes 62 Patency 62 Nilotinib 62 Echocardiographic 62 Carotid Endarterectomy 62 EURIDIS 62 Relapsing Remitting Multiple Sclerosis 61 PHPT 61 Lung Injury 61 Hematologic 61 renal artery stenting 61 Prospective Randomized Trial 61 Ischemic 61 Protease Inhibitors 61 pT2 61 randomized multicenter trial 61 dual endothelin receptor antagonist 61 Randomized Evaluation 61 randomized multicenter Phase III 61 Prospective Randomized 61 Multicenter 61 SYNTAX 61 Endarterectomy 61 Hematological 60 TAXUS ATLAS 60 sirolimus eluting stents 60 Prolongs Survival 60 Dual Antiplatelet Therapy 60 Overactive Bladder 60 Multicenter Study 60 ASTEROID 60 Multiethnic Study 60 STRIDE PD 60 Acute Ischemic Stroke 60 Thromboembolic 60 Histopathological 60 Intervention Trial 60 Diastolic Heart Failure 60 Placebo Controlled Trial 60 Renal Cell Carcinoma 60 Virologic 60 Xelox 60 Follicular Lymphoma 60 multicenter randomized controlled 60 trials RCTs 60 invasive aspergillosis 60 Squamous 60 Pivotal Study 60 Immunogenicity 60 invasive candidiasis 60 Stenting Trial CREST 60 Digital Mammographic Imaging 59 Interferon Beta 59 Venous Thromboembolism 59 Val HeFT 59 Clinical Outcome 59 metastatic neuroendocrine tumors 59 Platelet Inhibition 59 Inflammatory Markers 59 Immune Mediated 59 NICE SUGAR 59 Septic Shock 59 Metastatic Prostate Cancer 59 Efficacy Trial 59 Chronic Heart Failure 59 Combination REOLYSIN R 59 epoetin alpha 59 Drug Eluting 59 Neoplasms 59 Cardiotoxicity 59 MR Angiography 59 Cardiovascular Events 59 Unstable Angina 59 Aortic Stenosis 59 Severe Sepsis 59 Betaferon R 59 Adjuvant Therapy 59 Unfractionated Heparin 59 Fondaparinux 59 Hepatotoxicity 59 Ranolazine 59 Gastric Cancer 59 Atopic Dermatitis 59 Subtypes 59 prospective multicenter study 59 Meta Analysis 59 Fracture Risk 59 Erythropoietic 59 Myelodysplastic Syndromes 59 haematologic 59 Patients Treated With 59 Attack Trial ALLHAT 59 multicenter randomized clinical 59 COPERNICUS 59 substudy 59 colorectal neoplasms 59 Prophylactic Treatment 59 Cypher Sirolimus 59 Tocilizumab 59 subanalysis 59 Aggressive Reduction 59 RE LY ® 59 Stent Restenosis 59 Benign Prostatic Hyperplasia 59 Peripheral Arterial 59 GOUT 59 Renal Cancer 58 Allogeneic 58 Pivotal Trial 58 unfractionated heparin UFH 58 Clinical Trial Results 58 ACUITY trial 58 Natalizumab 58 Radiofrequency Ablation 58 abacavir Ziagen 58 Adverse Event 58 Chronic Prostatitis 58 Relapsing Multiple Sclerosis 58 Improves Outcomes 58 Patients Receiving 58 FDG PET imaging 58 JAK Inhibitor 58 B Cell Lymphoma 58 Hemodynamic 58 Allergic Rhinitis 58 Oral Fingolimod 58 Chronic Sinusitis 58 Long Term Efficacy 58 Nymox NX 58 Meta analyzes 58 Patient Outcomes 58 Thrombolysis 58 Autologous Stem Cell Transplantation 58 KRAS status 58 Hormone Refractory Prostate Cancer 58 Stent Thrombosis 58 liposomal amphotericin B 58 Coronary Artery Bypass Graft 58 relapsed MM 58 Malignancies 58 ARBITER 6 58 prospective multicentre 58 Phase IIIb clinical 58 Treatment Outcome 58 Pooled Analysis 58 Analytical Tool 58 Coronary Angiography 58 Heart Failure Patients 58 Nonalcoholic Fatty Liver Disease 58 cancer mCRC 58 Newly Diagnosed Multiple Myeloma 58 carotid artery stenting CAS 58 Adjuvant 58 Controlled Trial 58 RENAL 58 Contrast Agent 58 Pivotal Phase III 58 Left Ventricular Dysfunction 58 Lupus Nephritis 58 Cholesterol Levels SPARCL 58 Iron Overload 58 QT Prolongation 58 anterior uveitis 58 Breast Cancers 58 symptomatic intracranial 58 Breast Cancer Recurrence 58 Fungal Infections 58 Ovarian Cancer Screening 58 Neoadjuvant 58 Neoadjuvant Chemotherapy 58 VADT 58 Screening Trial 58 hepatic cirrhosis 58 Lupus Erythematosus 58 HER2 expression 57 Infarct 57 Myocardial Infarction 57 Prostatic 57 CT Angiography 57 Survival Rates 57 Angiographic 57 Adjunctive 57 Advanced Renal Cell 57 Pulmonary Arterial Hypertension 57 Adjuvant Chemotherapy 57 Myocardial Ischemia 57 Monotherapy 57 Nesiritide 57 Myocardial Infarction Study 57 Invasive Breast Cancer 57 Combination Treatment 57 Knee Osteoarthritis 57 Phase III Trial 57 Endometrial Cancer 57 Radiation Induced 57 Metabolic Endocrinology 57 Hypercholesterolemia 57 multicenter prospective 57 Ischaemic 57 Left Ventricular 57 cytomegalovirus infection 57 Radical Prostatectomy 57 Multicenter Trial 57 enterococcal 57 Advanced Melanoma 57 Invasive Fungal Infections 57 Stenting Trial 57 gastric carcinoma 57 Antiplatelet 57 WHIMS 57 intravesical therapy 57 metastatic malignant 57 Aliskiren 57 Anthracycline 57 #F FDG PET 57 Virus Infection 57 Clinical Relevance 57 Reperfusion Injury 57 Tigecycline 57 NEVO 57 Phase III Clinical Trial 57 Insulin Glargine 57 antigen PSA levels 57 Stenting 57 Bronchiectasis 57 demyelinating 57 atypical Hemolytic Uremic Syndrome 57 CLOTS 57 F FDG PET 57 immunochemical fecal occult 57 RE LY trial 57 Complicated Skin 57 Hormone Receptor Positive 57 ENESTnd 57 Thrombotic 57 Parathyroid Hormone 57 TMC# r 57 follicular lymphoma FL 57 Severe Asthma 57 BERKELEY CA UroToday.com 57 TRANSFORMS 57 Non Alcoholic Fatty 57 Bioequivalence 57 Metastases 57 Contrast Agents 57 Adenoma Prevention 57 cediranib 57 SORT OUT III 57 Patients Undergoing 57 paclitaxel eluting stents 57 Endometrial 57 Hepatocellular Carcinoma 57 Improved Survival 57 Interferon Alfa 57 RE LY 57 Rheumatoid Arthritis Patients 57 pT3 57 Phase 2b Clinical Trial 57 Randomized Trials 57 INCB# [003] 57 Dasatinib 57 Acute Coronary Syndromes 57 Aneurysm Repair 57 Percutaneous Coronary Intervention 57 Estrogen Receptor 57 relapsing remitting MS RRMS 57 Study Evaluating 57 randomized controlled clinical trials 57 Protelos 57 PRoFESS 57 REACH Registry 57 NAVISTAR R 57 Mantle Cell Lymphoma 57 Coagulation 57 Antiviral Therapy 57 Edge STudy 57 everolimus eluting stent 56 Safinamide 56 Systemic Lupus Erythematosus SLE 56 Rotavirus Vaccine 56 Prospective Multicenter 56 Cancer Incidence Mortality 56 APTIVUS R 56 Shows Promising 56 Enzyme Replacement Therapy 56 micafungin 56 Vertebral Fracture 56 Oral Mucositis 56 Pharmacodynamic 56 Adjuvant Treatment 56 gonococcal 56 Intravitreal 56 Replacement Therapy 56 retrospective cohort study 56 ST Segment Elevation 56 Neuroprotective Effects 56 Combination Therapy 56 Shows Efficacy 56 Vitro Activity 56 LV dysfunction 56 hypercholesterolaemia 56 recurrent GBM 56 EVEREST II 56 ER CHOP 56 Bacteremia 56 Embolization 56 endometrial carcinoma 56 grade squamous intraepithelial 56 Brain Metastases 56 Antitumor Activity 56 Phase IIIb study 56 Preterm Delivery 56 β blockers 56 Trandolapril 56 Hemorrhagic Stroke 56 Localized Prostate Cancer 56 multicenter multinational 56 Adalimumab 56 RoACTEMRA 56 Temsirolimus 56 Coronary Revascularization 56 Carotid Revascularization Endarterectomy vs. 56 ELISPOT 56 FluCAM arm 56 Randomized controlled 56 fluvastatin 56 ACTOS ® 56 colorectal adenoma 56 Lung Cancer Survival 56 Subgroup analyzes 56 Papillary 56 CYPHER Stent 56 Allergic Asthma 56 Serious Adverse Events 56 Chronic Renal Failure 56 Survival Benefit 56 fosamprenavir 56 Subgroup Analysis 56 phase IIIb 56 Prognostic Value 56 Statistically Significant 56 BZA CE 56 Iron Deficiency 56 nonmetastatic 56 Nexavar sorafenib 56 HPV-#/# 56 Acute Decompensated Heart Failure 56 Improve Survival 56 fluoroquinolone resistance 56 albumin excretion rate 56 prostate cancer CaP 56 Carcinomas 56 neoplasias 56 Immunologic 56 Critical Limb Ischemia CLI 56 Chronic Lymphocytic Leukemia 56 prostate cancer PCa 56 Phase Ib clinical 56 Chronic HCV 56 CIN2 + 56 canakinumab 56 Metastatic Renal Cell Carcinoma 56 Nebulized 56 Occlusive Disease 56 crizotinib PF # 56 recurrent venous thromboembolism 56 Diabetic Macular Edema 56 Lymphoid 56 Low Dose 56 Nonalcoholic Steatohepatitis 56 Clinical Evaluation 56 androgen suppression 56 plasma pharmacokinetics 56 Immunotherapeutic 56 Pemetrexed 56 Improves Survival 56 placebo controlled clinical 56 Soft Tissue Sarcoma 56 Atypical Hemolytic Uremic Syndrome 56 relapsing multiple sclerosis 56 ARCOXIA 56 Randomized Clinical Trial 56 atherothrombotic disease 56 ExTRACT TIMI 56 Helicobacter pylori eradication 56 Critical Limb Ischemia 56 multicentre randomized 56 Circulating Tumor Cells 56 Aggressive Drug Evaluation 56 Acute Myocardial 56 resected pancreatic cancer 56 Tumor Response 56 PLCO 56 ritonavir boosted 56 tigecycline 56 Daptomycin 56 Rheumatoid Arthritis RA 56 Erythropoiesis Stimulating Agent 56 SYNTAX trial 56 PREVENT IV 56 Infected Patients 56 Hemodialysis Patients 55 serum urate levels 55 carotid artery stenting 55 Motility 55 virological response 55 HER2 Positive Breast Cancer 55 Epirubicin 55 Bare Metal Stents 55 Insulin Therapy 55 IL#B 55 anti arrhythmic drug 55 Non Responders 55 Tyrosine Kinase Inhibitor 55 Bazedoxifene 55 clinical pharmacology studies 55 Lymph Node 55 Spine Patient Outcomes 55 adjuvant tamoxifen 55 Novel Oral 55 CP CPPS 55 Contrast Enhanced 55 Randomized Comparison 55 Postmenopausal Women 55 doxorubicin docetaxel 55 angiographically 55 Surgical Treatment 55 MADIT CRT trial 55 Anticoagulation 55 AADs 55 phase IIb trial 55 Molecular Weight Heparin 55 Bivalirudin 55 HIV seropositive 55 HER2 overexpression 55 Keratitis 55 zotarolimus eluting stent 55 fosbretabulin 55 Bone Mineral Density 55 symptomatic VTE 55 CIMZIA TM certolizumab pegol 55 Multicenter Randomized 55 Solid Tumors 55 Clinical Efficacy 55 serum lipid levels 55 Preclinical Study 55 Hydroxyurea 55 prucalopride 55 Eluting Stent 55 Erosive 55 Minimally Invasive Treatment 55 Glatiramer Acetate 55 CHAMPION PCI 55 MERIT ES 55 Premature Infants 55 Denufosol 55 Prostate Cancer Prevention 55 Percutaneous Tibial Nerve Stimulation 55 amifostine 55 invasive ductal 55 Gynecologic Oncology Group 55 Randomized Phase 55 RECORD1 55 BR.# study 55 sipuleucel T 55 postexposure prophylaxis 55 oncologic outcomes 55 metastatic gastric 55 AVERROES 55 Venous Thrombosis 55 ISAR TEST 55 heFH 55 CARE HF 55 riociguat 55 nulliparous women 55 Adefovir 55 Previously Treated 55 APTIVUS 55 velafermin 55 Randomized Controlled Trial 55 Endothelial Function 55 Risk Stratification 55 PD2i ® 55 Ultrasonography 55 Disease Progression 55 Doxil ® 55 Valsartan 55 BOLDER 55 Is Well Tolerated 55 Randomised 55 Neisseria gonorrhoeae 55 Intravascular 55 Restenosis 55 Ischemic Stroke 55 imipramine Tofranil 55 Sipuleucel T 55 Vitro Diagnostic 55 oral Hycamtin 55 Anti Tumor Activity 55 Novel Therapies 55 Fingolimod 55 clinicopathologic 55 multicenter phase 55 histologic subtype 55 Systemic Sclerosis 55 Lung Cancer Trial 55 Meets Primary Endpoint 55 Aromatase Inhibitors 55 Lenalidomide 55 HYVET 55 ABCB1 55 bendamustine 55 Asymptomatic Carotid 55 Unresectable 55 inhibitor RG# 55 SPIRIVA ® 55 Initiate Clinical Trial 55 Obese Patients 55 interferon gamma 1b 55 Computed Tomographic 55 prospective multicenter 55 recurrent glioblastoma multiforme 55 Erlotinib 55 Telmisartan 55 Vidaza azacitidine 55 urothelial bladder cancer 55 Postmarketing 55 AA Amyloidosis 55 homocysteine concentrations 55 salmeterol fluticasone propionate 55 Hodgkin lymphoma HL 55 Suicidality 55 Diabetic Neuropathy 55 Xanafide 55 Salivary 55 CIMZIA ™ 55 Epithelium 55 Beta Blocker 55 Confirms Efficacy 55 CTEPH 55 Liver Failure 55 Screening Trial DMIST 55 Advanced Colorectal Cancer 55 HBeAg negative patients 55 HoFH 55 Olmesartan 55 II Clinical Trial 55 Angioedema 55 Insulin detemir 55 Pediatric Patients 55 HuMax EGFr 55 echocardiographic parameters 55 dobutamine stress 55 Dacogen decitabine 55 Patients Treated 55 BEACOPP 55 SSc 55 APPRAISE 55 randomized Phase IIb 55 See CLINICAL PHARMACOLOGY 55 urothelial carcinoma 55 pimecrolimus cream 55 Clinical Outcomes Utilizing Revascularization 55 Cannabinoid 55 p# biomarker 55 Infarction 55 landmark ATHENA trial 55 Diabetic Patients 55 Recurrent Stroke 55 Randomized Controlled 55 Peginterferon 55 Cardiovascular Risk 54 Breast Density 54 malignant pleural mesothelioma 54 EUROCARE 54 S. maltophilia 54 ISEL 54 IgG antibody 54 HORIZONS AMI 54 Investigational Compound 54 Demonstrates Efficacy 54 #:#-# [033] 54 grade cervical intraepithelial 54 Vimpat ® lacosamide 54 oral FTY# 54 Adenoma 54 Secondary Hyperparathyroidism 54 Skeletal Muscle 54 venous thromboembolic disease 54 Pharmacokinetic 54 chemoprevention trials 54 Refractory Angina 54 PROSTVAC TM 54 CYP#D# inhibitor 54 dose atorvastatin 54 elevated LDH 54 cinacalcet 54 Achieves Primary Endpoint 54 Hepatitis B Virus 54 HSCT 54 longitudinal cohort study 54 Antiviral Activity 54 HCV Genotype 54 CYPHER R Sirolimus eluting 54 clinico pathological 54 Chemotherapy Induced 54 LHRH receptor positive 54 Pathogenesis 54 Study Demonstrates 54 ASCUS 54 prospective observational cohort 54 Systolic Hypertension 54 evaluating tivozanib 54 Troponin T 54 MenACWY 54 everolimus eluting stents 54 Calcium Acetate 54 perinatal outcomes 54 chronic HBV 54 GnRH agonists 54 Phase III Clinical Trials 54 Catheter Associated 54 Fluorouracil 54 candidemia 54 lipid elevations 54 GW# [003] 54 Pulmonary Artery 54 Ziprasidone 54 intravenous dosing 54 ISAR REACT 54 expressors 54 Exhaled Nitric Oxide 54 atherosclerotic renal artery stenosis 54 HCV RESPOND 2 54 retrospective cohort 54 ECASS 54 PROactive study 54 pain palliation 54 malignant neoplasms 54 Sustained Efficacy 54 Comorbidities 54 ATACAND 54 adenoma recurrence 54 KRAS mutation 54 SANTE 54 bronchoalveolar lavage 54 preclinical efficacy 54 vidofludimus 54 ENDEAVOR IV 54 Delayed Graft Function 54 intracranial hemorrhage ICH 54 Degarelix 54 Cutaneous T 54 Diabetes Hypertension 54 serum antibody 54 Serious Infections 54 multicenter randomized placebo controlled 54 Benign Prostatic Hyperplasia BPH 54 Immune Responses 54 baseline LDH 54 autologous SCT 54 thyroid carcinoma 54 Renal Tumors 54 Myocardial 54 TT genotype 54 Drug Candidate 54 Targeted Therapy 54 Myelofibrosis 54 gonococcal infection 54 Tiotropium 54 Confirmatory 54 Oxidative Stress 54 EBUS FNA 54 Prostate Lung Colorectal 54 AACR San Antonio 54 mycophenolate mofetil 54 Glucosamine Chondroitin Arthritis 54 Antiplatelet Therapy 54 Phase IIb Trial 54 RIO Lipids 54 ARIXTRA 54 ara C 54 salmeterol fluticasone 54 Pharmacokinetic Study 54 Azacitidine 54 biliary tract cancer 54 Oral Insulin Capsule 54 RE MODEL 54 pharmacodynamic parameters 54 interobserver 54 Targeted Therapies 54 HCV SPRINT 54 randomized controlled trials RCTs 54 CLARITY TIMI 54 Lp PLA 2 54 Moxifloxacin 54 TPV r 54 recurrent metastatic 54 Aggressive Prostate Cancer 54 Evaluable 54 Demonstrates Statistically Significant 54 delafloxacin 54 adalimumab Humira 54 Dialysis Outcomes 54 colorectal cancer CRC 54 Renal Function 54 Therapeutic Advances 54 tumor histology 54 BRIM3 54 liver transplant recipients 54 SF #v# 54 Somatostatin 54 HIV HCV coinfected 54 Fabry Disease 54 Progenitor Cells 54 Neuropathic Pain 54 Novel Mechanism 54 efaproxiral 54 mRCC 54 Platinol ® 54 HER2 amplification 54 Autoimmune Disease 54 tumor necrosis 54 Velcade bortezomib 54 beta interferons 54 Bladder Cancer 54 cardiac computed tomography 54 phase IIb study 54 lupus anticoagulant 54 Acute Coronary Syndrome 54 SABCS 54 Dupuytren Contracture 54 CTAP# Capsules 54 deletion 5q 54 external genital lesions 54 CC genotype 54 retrospective observational study 54 Diabetes Interventions 54 Aortic Dissection 54 chlamydial 54 Insulin Resistance 54 Pneumococcal Vaccine 54 complete cytogenetic response 54 Antitumor 54 PRECISE 54 Significantly Improves 54 Thrombin 54 Cystatin C 54 urodynamic 54 CALGB # [002] 54 pegylated liposomal doxorubicin 54 null responder 54 Leydig cell 54 Respiratory Symptoms 54 Tolvaptan 54 invasive lobular 54 Genetic Markers 54 anagrelide 54 prospective randomized controlled 54 Systematic Review 54 Lung Cancer Patients 54 bazedoxifene conjugated estrogens 54 Squamous Cell Carcinoma 54 ACOMPLIA R 54 grade glioma 54 caspofungin 54 thrombocytopenic 54 Inflammatory Arthritis 54 demonstrated antitumor activity 54 multicentric 53 PEG IFN 53 Partial Response 53 Atorvastatin Evaluation 53 Idiopathic Pulmonary Fibrosis 53 colorectal carcinomas 53 Corticosteroid 53 TG MV 53 longitudinal observational study 53 induce orthostatic hypotension 53 Elderly Patients 53 COPAXONE R 53 aldosterone antagonists 53 knee osteoarthritis OA 53 Dendritic Cells 53 Heterozygous Familial Hypercholesterolemia 53 Skin Lesions 53 careHPV 53 skeletal metastases 53 Phase 1a clinical 53 Hyperlipidemia 53 Treating Chronic 53 dose escalation clinical 53 Cholesterol Levels 53 assessing T DM1 53 adjuvant radiotherapy 53 Teriparatide 53 #:#-# [031] 53 symptomatic BPH 53 Pivotal Phase 53 ABCSG 53 malignant neoplasm 53 RRMS patients 53 Flu Cy 53 Diabetic Nephropathy 53 stage IIIB 53 LNG IUS 53 Renal Transplantation 53 Cimzia TM 53 gefitinib Iressa 53 multicentre study 53 metaanalysis 53 fluoroquinolone resistant 53 Quinamed 53 clinicopathological 53 Progressive Multifocal Leukoencephalopathy 53 serologic testing 53 Anticoagulant 53 Phase 2b Study 53 Bone Metastases 53 ACE Inhibitors 53 macrovascular disease 53 gastric adenocarcinoma 53 Antihypertensive 53 HER2 Positive 53 malignant lymphoma 53 tipranavir 53 Feasibility Trial 53 p# antigen 53 Intracranial 53 Dalbavancin 53 Fulvestrant 53 Endovascular Treatment 53 Ovarian PLCO Cancer 53 Hepatocellular Carcinoma HCC 53 PREDICTIVE 53 Malignant Glioma 53 Hypotension 53 Mouse Model 53 postoperative AF 53 Pafuramidine 53 undergone radical prostatectomy 53 observational cohort study 53 clevidipine 53 vaginal lesions 53 neutropaenia 53 gadobutrol 53 carotid atherosclerosis 53 antiretroviral naïve 53 liver metastasis 53 Non Alcoholic Steatohepatitis 53 mammographic density 53 AVADO 53 Relapsed Refractory 53 Pharmacologic 53 Betaferon ® 53 recurrent malignant glioma 53 sunitinib malate 53 Inflammatory Diseases 53 malignant ascites 53 Acute Heart Failure 53 Polyneuropathy 53 Double Blind Randomized 53 ano genital warts 53 RezularTM 53 CLINICAL PHARMACOLOGY 53 seropositivity 53 oral deforolimus 53 prospective observational 53 pharmacodynamic PD 53 DAS# CRP 53 epithelial tumors 53 darunavir r 53 eculizumab therapy 53 T1DM 53 BCIRG 53 IFN α 53 Intervention Effectiveness 53 PRE SURGE 53 sorafenib Nexavar 53 adjuvant therapies 53 neutrophil counts 53 Therapeutic Effects 53 Lowers Risk 53 desvenlafaxine succinate 53 SPIRIT IV 53 ERSPC 53 multivariable adjusted 53 Epidermal Growth Factor Receptor 53 See WARNINGS 53 Diagnostic Tests 53 Epratuzumab 53 CABG Surgery 53 viral kinetics 53 VICTOR E3 53 prospectively defined 53 Protein Expression 53 Femara letrozole 53 Transurethral 53 Multicenter Automatic Defibrillator Implantation 53 PEGylated interferon beta 1a 53 colorectal liver metastases 53 Cimzia certolizumab pegol 53 postmenopausal osteoporotic women 53 RNAi Therapeutic 53 Autoantibodies 53 rFSH 53 Antiepileptic Drug 53 Clinical Trial Data 53 Solid Tumours 53 Microalbuminuria 53 leukotriene receptor antagonists 53 urothelial cancer 53 underwent resection 53 HORIZONS AMI trial 53 corrected QT interval 53 Ultrasensitive 53 Urinary Incontinence 53 depsipeptide 53 CIN3 53 postoperative mortality 53 teriflunomide 53 CYT# potent vascular disrupting 53 nonsmall cell lung cancer 53 Contraindications 53 etanercept Enbrel 53 prostate carcinoma 53 Roche Xeloda 53 CUSTOM III 53 transthyretin TTR mediated amyloidosis 53 Drug Shows Promise 53 Demonstrates Positive 53 exploratory endpoints 53 median survivals 53 murine model 53 Postmenopausal 53 PERSEUS 53 RECIST Response Evaluation Criteria 53 Autoimmune Diseases 53 PHASE III 53 sirolimus eluting 53 Tipranavir 53 phase IIb clinical 53 Ischemia 53 ACCORD Lipid 53 BARACLUDE ® 53 phase Ib clinical 53 mesilate 53 ancrod 53 Breast Tumors 53 Infliximab 53 thalidomide Thalomid 53 Acute Coronary Syndromes ACS 53 low expressors 53 Gleevec resistant 53 STEP BD 53 ILLUSTRATE 53 placebo controlled Phase III 53 #:#-# [023] 53 Intravesical 53 Potent Antiviral Activity 53 Long Term Outcomes 53 Bronchodilator 53 Endocrine Therapy 53 Vicriviroc 53 Vasogen Celacade 53 Sorafenib HCC Assessment 53 Taxotere ® 53 Postmenopausal Osteoporosis 53 PROSTVAC VF 53 Bacterial Vaginosis 53 Significantly Reduces 53 Recurrent Breast Cancer 53 neoadjuvant 53 AVONEX ® 53 LUMINATE 53 GISSI 53 BR.# 53 MGd 53 Embolic Protection 53 deferiprone 53 DASISION 53 NCT# ClinicalTrials.gov 53 Gene Mutation 53 Clinical Trials Review 53 Phase IIb Clinical Trial 53 International Prognostic Scoring 53 chest radiographs 53 Angiotensin Converting Enzyme 53 Kidney Function 53 Successfully Treated 53 mg BID dose 53 Transdermal Patch